Related Experiment Videos
The OPG/RANKL/RANK system in metabolic bone diseases
L C Hofbauer1, C A Kühne, V Viereck
1Philipps-University, Marburg, Germany. hofbauer@post.med.uni-marburg.de
Journal of Musculoskeletal & Neuronal Interactions
|December 24, 2004
Summary
The OPG/RANKL/RANK system regulates bone health. Imbalances in this system contribute to metabolic bone diseases like osteoporosis and hyperparathyroidism, suggesting RANKL antagonists as potential therapies.
Area of Science:
- Bone Biology and Metabolic Diseases
- Endocrinology and Immunology
Background:
- The OPG/RANKL/RANK cytokine system is crucial for osteoclast function and bone remodeling.
- Alterations in this system are implicated in various human metabolic bone diseases, including osteoporosis and hyperparathyroidism.
Purpose of the Study:
- To summarize OPG/RANKL/RANK abnormalities in different forms of osteoporosis and hyperparathyroidism.
- To explore the role of this system in estrogen deficiency, glucocorticoid use, immobilization, and hyperparathyroidism.
Main Methods:
- Review of existing studies on OPG/RANKL/RANK system in metabolic bone diseases.
- In vitro and in vivo investigations of hormonal and mechanical influences on OPG and RANKL expression.
- Analysis of OPG administration in animal models and a clinical study.
Main Results:
- Estrogen agonists increase OPG production; estrogen deficiency up-regulates RANKL.
- Glucocorticoids and immunosuppressants increase RANKL and decrease OPG.
- Mechanical strain inhibits RANKL and up-regulates OPG; lack of strain enhances RANKL/OPG ratio.
- Chronic PTH exposure increases RANKL and decreases OPG.
Conclusions:
- Imbalances in the RANKL/OPG ratio are a likely cause of bone loss in metabolic bone diseases.
- OPG administration can prevent bone loss in models of estrogen deficiency.
- Targeting the RANKL/OPG system, potentially with a RANKL antagonist, shows therapeutic promise for metabolic bone diseases.